Different Amoxicillin Treatment Regimens in Erythema Migrans Patients
NCT ID: NCT03966014
Last Updated: 2025-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
510 participants
INTERVENTIONAL
2019-06-01
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AMS VS MOXI Ketek vs Avelox in AMS
NCT00537563
A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections
NCT00643292
Short Course of Amoxicillin for Erysipelas
NCT01059123
Comparing Short to Standard Amoxicillin Course for Erysipelas
NCT07104552
Zmax Compared to Augmentin in Sinusitis
NCT00367120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EM-amoxicillin 3 x 10 days
EM-amoxicillin 3 x 10 days
Patients will receive amoxicillin 500 milligram tid for 10 days
EM-amoxicillin 3 x 14 days
EM-amoxicillin 3 x 14 days
Patients will receive amoxicillin 500 milligram tid for 14 days
EM-amoxicillin 2 x 14 days
EM-amoxicillin 2 x 14 days
Patients will receive amoxicillin 500 milligram bid for 14 days
Controls
Controls
No intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EM-amoxicillin 3 x 10 days
Patients will receive amoxicillin 500 milligram tid for 10 days
EM-amoxicillin 3 x 14 days
Patients will receive amoxicillin 500 milligram tid for 14 days
EM-amoxicillin 2 x 14 days
Patients will receive amoxicillin 500 milligram bid for 14 days
Controls
No intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* extracutaneous manifestations of Lyme borreliosis
* immunocompromising state
* serious adverse event to beta lactam antibiotic
* receiving antibiotic with antiborrelial activity within 10 days
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Ljubljana School of Medicine, Slovenia
OTHER
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daša Stupica
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daša Stupica, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Infectious Diseases, University Medical Centre Ljubljana, Slovenia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Centre Ljubljana
Ljubljana, , Slovenia
University Medical Centre Ljubljana
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Amoxy 10-15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.